Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in guinea-pig

1745-9974-3-10 1745-9974 Research Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in guinea-pig Leung Sum Yee sumyeeleung@hotmail.com Niimi Akio niimi@kuhp.kyoto-u.ac.jp Williams S Alison alison.williams@imperial.ac.uk Nath Puneeta puneeta.nath@novartis.com Blanc F-Xavier xavier.blanc@bct.aphp.fr Dinh Q Thai q-thai.dinh@charite.de Chung K Fan f.chung@imperial.ac.uk

Thoracic medicine, National Heart & Lung Institute, Imperial College, London, UK

Department of respiratory medicine, Graduate school of medicine, Kyoto University, Japan

Department of internal medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany

Department of respiratory medicine, Chang Gung Memorial Hospital, Kaohsiung medical centre, Taiwan

Cough 1745-9974 2007 3 1 10 http://www.coughjournal.com/content/3/1/10 18154688 10.1186/1745-9974-3-10 03 12 2006 23 12 2007 23 12 2007 2007 Leung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Cough reflex can be induced by the pepper extract capsaicin and by low pH in guinea-pig airways. Transient receptor potential vanniloid-1 (TPRV-1) is expressed in the sensory and afferent nerve fibres in airways.

Objective

We hypothesized that a novel pyridazinylpiperazine analog TPRV-1 inhibitor can effectively reduce cough reflex stimulated by citric acid and capsaicin.

Methods

Guinea pigs were injected with specific TPRV-1 inhibitor, V112220, a pyridazinylpiperazine analog of N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carbox-amide (BCTC) (3 mg/kg) intra-peritoneally. One hour before cough response assessment. Coughs were recorded using a recorder system that identified cough sound and accompanying expiratory flows, distinct from sneezes. Guinea-pigs exposed to citric acid (0.4 M) and to capsaicin (10^-4M) aerosols, in succession separately by 2 hours.

Results

V112220 significantly inhibited the number of coughs induced by citric acid (73 ± 11%, p < 0.01) and capsaicin (70 ± 9.4%, p < 0.05) compared to vehicle control.

Conclusion

A novel pyridazinylpiperazine analog TPRV-1 inhibitor can inhibit the cough reflex, induced by both low pH and capsaicin, suggesting that it could be clinically beneficial in treatment of cough.

Introduction

Capsaicin is a potent tussive agent in most species including humans. It activates a capsaicin receptor, transient receptor potential vanilloid-1 (TRPV-1), which is a polymodal ion channel 1 that is activated by stimuli other than capsaicin such as, heat, acid 2 and endogenous compounds such as anandamide, bradykinin and endocannabinoids 134. Acidification of the airway in guinea-pig also activates A-δ fibres and vagal C-fibre nerves, partly through activation of TRPV-1 56. TRPV-1 expression has been found in epithelial nerves in guinea-pig and in humans 789; in chronic cough patients, the expression of TRPV-1 in epithelial nerves is enhanced 7.

Several antagonists of TRPV-1 have now been described 10. Capsazepine is one of the first antagonists described, and blocks cough induced by capsaicin and citric acid 111213. In addition, other antagonists such as iodo-resiniferatoxin and BCTC have also been shown to reduce capsaicin and citric acid cough in guinea-pigs 1415. We investigated the effect of a novel and more selective TRPV-1 antagonist 161718, V112220, on cough induced by capsaicin and citric acid in the conscious guinea-pig.

Materials and methods

The protocols were approved by the Imperial College BioSciences Group and performed under a Project License from the British Home Office, UK, under the Animals (Scientific Procedures) Act 1986.

Animals

Pathogen free Male Hartley guinea pigs (600 – 700 g) were used for the study. Animals were screened one week before the in vivo cough examination.

Reagents

Materials used in the study including: V112220, a selective TRPV1 antagonist (Purdue Pharma, Ardsley, New York); vehicle, 20% hydroxypropyl-β cyclodextrin (Sigma, Dorset, UK); Procaterol hydrochloride (Sigma, Dorset, UK); Citric Acid (Sigma, Dorset, UK) and Capsaicin (Sigma, Dorset, UK).

Pre-screening of animals

Conscious guinea pigs were pre-screened to assess their cough response to 0.4 M citric acid one week before the cough study with V112220 or diluent. Low responders (number of coughs < 3) and high responders (number of coughs > 20) were excluded from the study. After pre-screening, animals were allocated into 3 different groups, the control group (n = 4) and two treatment groups (either with V112220 or vehicle, n = 5).

In vivo cough measurements

Conscious animals were placed in a 4 L plethysmograph which was equipped with an internal microphone and a pressure transducer, and were connected to a Amplifier Interface Unit series pre-amplifier (EMMS, Hants, UK). Aerosols were generated with an ultrasonic nebuliser (DeVilbiss, London, UK) which was connected to a Basic Flow Supplier AIR 200 (EMMS, Hants, UK). Airflow was set at 8 L/min. Coughs were detected in three ways: via the microphone, via the pressure transducer and by observing the guinea-pig behaviour which was also captured with an external camera. Data acquisition was performed with the eDacq (EMMS, Hants, UK) acquisition software.

Protocol

One week following screening, guinea pigs in the treatment groups were injected with either 1 ml of vehicle or 3 mg/kg V112220 intra-peritoneally (i.p.) 1 hour before cough response assessment. Each guinea pig received 0.1 mg/kg procaterol hydrochloride i.p. injection 10 minutes prior to each cough assessment in order to minimise bronchoconstriction. For cough assessment, animals were exposed to 0.4 M citric acid for 10 min and a 10 min cough response was recorded. Two hours following citric acid inhalation, the same animal was exposed to 10^-4M Capsaicin for 10 min and the cough response was assessed.

Data analysis

Data were recorded as number of coughs per 10 min assessment. Cough numbers of individual animal were compared among pre-screening, following citric acid inhalation and following capsaicin inhalation. Data from the treatment groups were compared with the control group. Mean values were statistically analyzed by one-way analysis of variance (ANOVA) to evaluate significant differences between groups. Values are expressed as means and 95%CI, with p < 0.05 being considered significant.

Results

Pre-screening of animals

Guinea-pigs (n = 24) were pre-screened regarding their cough response with citric acid. Ten guinea-pigs (8 low and 2 high cough responders) were excluded and subsequently, fourteen guinea-pigs were divided into 3 groups. No significant difference in baseline cough response was noted among the 3 groups of guinea pigs. Figure 1 shows the number of coughs in the 3 different groups for each guinea-pig and the number of coughs following exposure to citric acid and capsaicin at a later date either after no treatment (control) or after vehicle or after V112220 treatment.

Figure 1

Number of coughs per 10 min in conscious guinea-pigs on pre-screen, following exposure to citric acid and to capsaicin

Number of coughs per 10 min in conscious guinea-pigs on pre-screen, following exposure to citric acid and to capsaicin. Left panel shows the response in the control group, the central panel the response from vehicle-treated group, and the right panel the effect of treatment with V112220.

Effect of V112220

Figure 2 shows the mean cough number with 95% CI for the 3 groups of guinea-pigs for control, vehicle- and V112220-treated group. Vehicle treatment did not significantly change the number of coughs induced by either citric acid or capsaicin exposure. V112220 treatment (mean ± SEM: 2.6 ± 1.1; -0.4 to 5.6 coughs/10 min, p < 0.01) significantly reduced the number of coughs induced by citric acid compared to vehicle treatment (9.6 ± 1.6; 5.2 to 14.0 cough/10 min). V112220 treatment (2.6 ± 0.8; 0.3 to 4.9 coughs/10 min, p < 0.05) also significantly decreased the number of coughs compared to vehicle treatment (8.6 ± 0.7; 6.7 to 10.5 cough/10 min) for capsaicin. V112220 reduced citric acid-induced cough response by 73 ± 11% compared to vehicle treatment whereas capsaicin-induced cough response was reduced by 70 ± 9.4%.

Figure 2

Number of coughs following citric acid or capsaicin exposure

Number of coughs following citric acid or capsaicin exposure. Left panel show results from citric acid exposure while the right panel the results from capsaicin exposure. Data shown as mean ± 95% CI (*, ** p < 0.05 and 0.01 compared to vehicle treatment).

Discussion

Our study demonstrated that blockade of the TRPV-1 receptors with a selective inhibitor, V112220, which is a pyridazinylpiperazine derivative, effectively decreased by 70% coughs evoked by citric acid or capsaicin aerosol exposure in the guinea pig. This is in agreement with a previous study using the earlier TRPV-1 antagonist, capsazepine, which inhibited coughs induced by citric acid or capsaicin but not coughs induced by 7% hypertonic saline solution12. In addition, there have been other studies with other TRPV-1 antagonists such as iodo-resiniferatoxin and BCTC that have shown inhibition of cough induced by citric acid and capsaicin in the guinea-pig 1415.

Recently, 4-(2-pyridyl)piperazine-1-carboxamide analogues as potent TRPV-1 antagonists have been developed 19. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC), a member of that new chemical series, was a highly potent TRPV-1 antagonist that effectively reverses the behavioral effects of inflammatory and neuropathic pain in rats 161719 but is poor in metabolic stability, short half-life, aqueous solubility, and in oral bioavailability 18. Nevertheless, BCTC when administered intraperitoneally (30 mg/kg) one hour before capsaicin cough challenge caused an inhibition of capsaicin cough by 65% maximally 15. A newer series of pyridazinylpiperazine compounds with improved pharmaceutical and pharmacological properties of BCTC was developed leading to V112220 which we used in this study. V112220 is similar to V113886, another pyridazinylpiperazine derivative of BCTC 18. The plasma half-life of this compound after administration intravenously or by gavage is reported to be around 6 hours in the rat 18. For this reason, we performed capsaicin challenge after citric acid challenge on the basis that the compound would still maintain significant plasma levels for many hours after dosing. The degree of inhibition of capsaicin- and citric acid-cough by V112220 we observed was similar with 70% reduction of the induced cough. However, capsaicin- and citric acid-cough were not completely inhibited by V112220. The incomplete inhibition, particularly of capsaicin-induced cough may indicate that higher dose of V112220 may be needed for complete inhibition, since cough response induced by capsaicin is presumed to be entirely mediated by TRPV-1. However, further studies with higher doses will be needed to answer this issue.

TRPV1 is sensitive to vanilloid molecules, including capsaicin. It can be activated by low extracellular pH 262021, and by the endocannabionid, anandamide 22, lipoxygenase metabolites 23 and N-arachidonoyl-dopamine 24, and also by a change in temperature 25. TRPV1 is highly expressed in a subset of primary sensory neurons of the trigeminal, vagal and dorsal root ganglia with C- and A-δ fibres 9. These receptors are polymodal nociceptors. TRPV1 excites terminals of primary sensory neurons and causes the initiation of action potentials of reflex responses, such as cough in airways 26. It may also cause a series of neurogenic inflammation via antidromic conduction of action potential to collateral nerve fibres 26. Capsaicin is one of the most tussigenic stimuli available in conscious animals and humans, and TRPV1 has been identified as a possible component of the cough receptor in guinea pigs and humans 27. Inflammatory stimuli such as prostaglandins, bradykinin, and nerve growth factor may upregulate the expression and function of TRPV-1 282930. Chronic airway inflammation such as in asthma or COPD may increase the sensitivity of TRPV-1 to its agonists and trigger the cough reflex 27. The expression of TRPV-1 in the epithelial airway nerves of patients with chronic persistent cough of diverse causes and with an enhanced capsaicin cough response has a 3-fold increase of TRPV-1 expression 7. TRPV-1 receptors may therefore contribute to the enhanced cough reflex and the cough response in chronic persistent cough

Chronic persistent cough is a clinical problem, since antitussives available to control cough are often not effective 31. More potent antitussives are needed. TRPV-1 antagonists may represent a potential class of antitussives that could be useful in the control of chronic persistent cough.

Authors' contributions

SYL carried out the drugs administration and cough measurements, and performed the statistical analysis. AN helped in the design of the study. ASW & PN participated in animal maintenance. F-XB & QTD assisted in cough measurement, and drugs preparation. KFC conceived of the study, and participated in its coordination. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to Purdue Pharma (Ardsley, New York) for supplying the selective TRPV1 antagonist, V112220. We thank EMMS (Hants, UK) for technical assistance on cough measurement. FXB was the recipient of a travel grant from the French Société de Pneumologie de Langue Française and from the Chancellerie des Universités de Paris (legs Poix).

The vanilloid receptor: a molecular gateway to the pain pathway Caterina MJ Julius D Annu Rev Neurosci 2001 24 487 517 10.1146/annurev.neuro.24.1.487 11283319 The cloned capsaicin receptor integrates multiple pain-producing stimuli Tominaga M Caterina MJ Malmberg AB Rosen TA Gilbert H Skinner K Raumann BE Basbaum AI Julius D Neuron 1998 21 531 543 10.1016/S0896-6273(00)80564-4 9768840 The anandamide transport inhibitor AM404 activates vanilloid receptors Zygmunt PM Chuang H Movahed P Julius D Hogestatt ED Eur J Pharmacol 2000 396 39 42 10.1016/S0014-2999(00)00207-7 10822052 Induction of vanilloid receptor channel activity by protein kinase C Premkumar LS Ahern GP Nature 2000 408 985 990 10.1038/35050121 11140687 Activation of bronchopulmonary vagal afferent nerves with bradykinin, acid and vanilloid receptor agonists in wild-type and TRPV1-/- mice Kollarik M Undem BJ J Physiol 2004 555 115 123 1664811 14634201 10.1113/jphysiol.2003.054890 Acid-sensitive vagal sensory pathways and cough Kollarik M Ru F Undem BJ Pulm Pharmacol Ther 2007 20 402 411 10.1016/j.pupt.2006.11.010 17289409 Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough Groneberg DA Niimi A Dinh QT Cosio B Hew M Fischer A Chung KF Am J Respir Crit Care Med 2004 170 1276 1280 10.1164/rccm.200402-174OC 15447941 Immunohistochemical localization of vanilloid receptor subtype 1 (TRPV1) in the guinea pig respiratory system Watanabe N Horie S Michael GJ Spina D Page CP Priestley JV Pulm Pharmacol Ther 2005 18 187 197 10.1016/j.pupt.2004.12.002 15707853 Sensory transduction in cough-associated nerves Kollarik M Undem BJ Respir Physiol Neurobiol 2006 152 243 254 16443402 Drugs to suppress cough Chung KF Expert Opin Investig Drugs 2005 14 19 27 10.1517/13543784.14.1.19 15709918 Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin Bevan S Hothi S Hughes G James IF Rang HP Shah K Walpole CS Yeats JC Br J Pharmacol 1992 107 544 552 1907893 1422598 Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs Lalloo UG Fox AJ Belvisi MG Chung KF Barnes PJ J Appl Physiol 1995 79 1082 1087 8567546 Synergistic interactions between airway afferent nerve subtypes regulating the cough reflex in guinea-pigs Mazzone SB Mori N Canning BJ J Physiol (Lond) 2005 569 559 573 1464254 16051625 10.1113/jphysiol.2005.093153 Antitussive activity of iodo-resiniferatoxin in guinea pigs Trevisani M Milan A Gatti R Zanasi A Harrison S Fontana G Morice AH Geppetti P Thorax 2004 59 769 772 10.1136/thx.2003.012930 15333853 TRPV1 antagonists attenuate antigen-provoked cough in ovalbumin sensitized guinea pigs McLeod RL Fernandez X Correll CC Phelps TP Jia Y Wang X Hey JA Cough 2006 2 10 1764418 17173683 10.1186/1745-9974-2-10 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties Valenzano KJ Grant ER Wu G Hachicha M Schmid L Tafesse L Sun Q Rotshteyn Y Francis J Limberis J Malik S Whittemore ER Hodges D J Pharmacol Exp Ther 2003 306 377 386 10.1124/jpet.102.045674 12721338 N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain Pomonis JD Harrison JE Mark L Bristol DR Valenzano KJ Walker K J Pharmacol Exp Ther 2003 306 387 393 10.1124/jpet.102.046268 12721336 Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists Tafesse L Sun Q Schmid L Valenzano KJ Rotshteyn Y Su X Kyle DJ Bioorg Med Chem Lett 2004 14 5513 5519 10.1016/j.bmcl.2004.09.010 15482915 4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists Sun Q Tafesse L Islam K Zhou X Victory SF Zhang C Hachicha M Schmid LA Patel A Rotshteyn Y Valenzano KJ Kyle DJ Bioorg Med Chem Lett 2003 13 3611 3616 10.1016/S0960-894X(03)00759-5 14505681 Protons: small stimulants of capsaicin-sensitive sensory nerves Bevan S Geppetti P Trends Neurosci 1994 17 509 512 10.1016/0166-2236(94)90149-X 7532332 Low pH-induced release of calcitonin gene-related peptide from capsaicin-sensitive sensory nerves: mechanism of action and biological response Geppetti P Del Bianco E Patacchini R Santicioli P Maggi CA Tramontana M Neuroscience 1991 41 295 301 10.1016/0306-4522(91)90218-D 1711653 Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Zygmunt PM Petersson J Andersson DA Chuang H Sorgard M Di M V Julius D Hogestatt ED Nature 1999 400 452 457 10.1038/22761 10440374 Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances Hwang SW Cho H Kwak J Lee SY Kang CJ Jung J Cho S Min KH Suh YG Kim D Oh U Proc Natl Acad Sci U S A 2000 97 6155 6160 18574 10823958 10.1073/pnas.97.11.6155 An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors Huang SM Bisogno T Trevisani M Al Hayani A De Petrocellis L Fezza F Tognetto M Petros TJ Krey JF Chu CJ Miller JD Davies SN Geppetti P Walker JM Di M V Proc Natl Acad Sci U S A 2002 99 8400 8405 123079 12060783 10.1073/pnas.122196999 The capsaicin receptor: a heat-activated ion channel in the pain pathway Caterina MJ Schumacher MA Tominaga M Rosen TA Levine JD Julius D Nature 1997 389 816 824 10.1038/39807 9349813 The transient receptor potential vanilloid 1: role in airway inflammation and disease Geppetti P Materazzi S Nicoletti P Eur J Pharmacol 2006 533 207 214 10.1016/j.ejphar.2005.12.063 16464449 Cough {middle dot} 5: The type 1 vanilloid receptor: a sensory receptor for cough Morice AH Geppetti P Thorax 2004 59 257 258 10.1136/thx.2003.013482 14985566 Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition Chuang HH Prescott ED Kong H Shields S Jordt SE Basbaum AI Chao MV Julius D Nature 2001 411 957 962 10.1038/35082088 11418861 The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase De Petrocellis L Harrison S Bisogno T Tognetto M Brandi I Smith GD Creminon C Davis JB Geppetti P Di M V J Neurochem 2001 77 1660 1663 10.1046/j.1471-4159.2001.00406.x 11413249 p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia Ji RR Samad TA Jin SX Schmoll R Woolf CJ Neuron 2002 36 57 68 10.1016/S0896-6273(02)00908-X 12367506 Assessment and measurement of cough: the value of new tools Chung KF Pulm Pharmacol Ther 2002 15 267 272 10.1006/pupt.2002.0360 12099776